vs
Side-by-side financial comparison of LENZ Therapeutics, Inc. (LENZ) and SOLAI Ltd (SLAI). Click either name above to swap in a different company.
LENZ Therapeutics, Inc. is the larger business by last-quarter revenue ($12.5M vs $11.0M, roughly 1.1× SOLAI Ltd). SOLAI Ltd runs the higher net margin — -126.2% vs -133.6%, a 7.4% gap on every dollar of revenue. LENZ Therapeutics, Inc. produced more free cash flow last quarter ($-9.0M vs $-17.0M).
LENZ Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing novel ophthalmic therapies. Its lead product candidates address presbyopia, the age-related loss of near vision, catering to global patient groups with unmet medical needs in the eye care sector.
LENZ vs SLAI — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $11.0M |
| Net Profit | $-16.7M | $-13.9M |
| Gross Margin | — | 0.1% |
| Operating Margin | -151.1% | -126.2% |
| Net Margin | -133.6% | -126.2% |
| Revenue YoY | — | -43.1% |
| Net Profit YoY | -63.5% | -173.4% |
| EPS (diluted) | $-0.59 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $12.5M | — | ||
| Q2 25 | $5.0M | $11.0M | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | $19.4M |
| Q3 25 | $-16.7M | — | ||
| Q2 25 | $-14.9M | $-13.9M | ||
| Q3 24 | $-10.2M | — | ||
| Q2 24 | $-10.3M | $18.9M |
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 52.4% |
| Q3 25 | -151.1% | — | ||
| Q2 25 | -337.1% | -126.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.6% |
| Q3 25 | -133.6% | — | ||
| Q2 25 | -298.2% | -126.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 97.9% |
| Q3 25 | $-0.59 | — | ||
| Q2 25 | $-0.53 | $-0.01 | ||
| Q3 24 | $-0.38 | — | ||
| Q2 24 | $-0.40 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $25.4M | $1.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $193.9M | $43.8M |
| Total Assets | $210.7M | $69.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $25.4M | — | ||
| Q2 25 | $37.6M | $1.2M | ||
| Q3 24 | $41.0M | — | ||
| Q2 24 | $84.0M | $2.3M |
| Q3 25 | $193.9M | — | ||
| Q2 25 | $206.4M | $43.8M | ||
| Q3 24 | $215.3M | — | ||
| Q2 24 | $192.9M | $45.9M |
| Q3 25 | $210.7M | — | ||
| Q2 25 | $217.3M | $69.1M | ||
| Q3 24 | $224.0M | — | ||
| Q2 24 | $202.6M | $63.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.6M | $-17.0M |
| Free Cash FlowOCF − Capex | $-9.0M | $-17.0M |
| FCF MarginFCF / Revenue | -72.2% | -154.2% |
| Capex IntensityCapex / Revenue | 3.5% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-47.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-8.6M | — | ||
| Q2 25 | $-11.5M | $-17.0M | ||
| Q3 24 | $-10.6M | — | ||
| Q2 24 | $-15.8M | $-12.1M |
| Q3 25 | $-9.0M | — | ||
| Q2 25 | $-11.7M | $-17.0M | ||
| Q3 24 | $-10.8M | — | ||
| Q2 24 | $-15.9M | — |
| Q3 25 | -72.2% | — | ||
| Q2 25 | -235.0% | -154.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | 3.5% | — | ||
| Q2 25 | 4.8% | 0.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LENZ
Segment breakdown not available.
SLAI
| Data center | $6.5M | 59% |
| Cryptocurrency mining | $4.6M | 41% |
